Home › Companies › KTTA

Pasithea Therapeutics Corp.

KTTA Lead: Phase 1 1 Biotech Distilled article ↓

Neurology Oncology Small Molecule

Most recent annual filing: 2026-03-30

Pipeline (3 active programs)

PAS-004

Small Molecule Target: MEK 1, MEK 2

Neurofibromatosis Type 1 Preclinical oral
Undisclosed indication Phase 1 oral

PAS-001

Small Molecule Target: C4A

Schizophrenia Preclinical

Discontinued (1)

PAS-003 — Amyotrophic Lateral Sclerosis · ceased further development due to significant capital, resources and time required to develop the program

Biotech Distilled coverage (1)

2026-05-16 Pasithea Therapeutics (KTTA) - Scientific Deep Dive for PAS-004 and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.